Education Library

“The decision to escalate, de-escalate or wean is highly dependent on patient presentation, capabilities of the institution, and the expertise of the heart team,” write the authors of this paper on differential usage of Impella devices, extracorporeal membrane oxygenation (ECMO), and combined str

In this paper the authors discuss best practices for monitoring CS patients supported by a microaxial flow pump (mAFP) such as Impella®, venoarterial extracorporeal membrane oxygenation (VA ECMO), or both devices together, a combination referred to as ECpella. 

In their recently published paper titled “Timing and Treatment Strategies According to SCAI Classification in Cardiogenic Shock,” Giuseppe Tarantini and colleagues describe a “4-early step” approach for timely management of patients with acute myocardial infarction cardiogen

Kaveh Eghbalzadeh, MD, PhD, describes his first experiences with awake insertion of the Impella 5.5® with SmartAssist® in Cologne.

Letizia Bertoldi, MD, and colleagues describe how catecholamines and percutaneous ventricular assist devices (pVADs) are used to treat cardiogenic shock (CS). Bertoldi et al.

This paper discusses the latest guidance for identifying patients with cardiogenic shock (CS) who are candidates for mechanical circulatory support (MCS).

Experts throughout Europe have contributed to this European Heart Journal supplement with articles discussing best practices for successfully managing mechanical circulatory support (MCS) in patients with cardiogenic shock.

Mario Iannaccone, MD, discusses how he and his team managed an urgent cardiogenic shock case that arrived on a Saturday morning.

William O’Neill, MD, defines high-risk PCI and explains how to decide when to use mechanical circulatory support in this short interview.

Alejandro F. Lemor, MD, disusses A-SMART-EF, a new risk score for predicting outcomes in patients supported with Impella® during PCI.

Alexander Bernhardt, MD, discusses the preoperative, intraoperative, and postoperative use of Impella® in cardiac surgery.

Learn more about the data and differences between part I and part II from the York data analysis.

In the presentation titled “Predictive value of residual SYNTAX score for clinical outcomes after high-risk percutaneous coronary intervention: Evidence from pooled analysis of prospective studies,” Vasileios Panoulas, MD, and colleagues...

Vasileios Panoulas, MD, discusses a pooled analysis of factors predicting outcomes at 90 days in high-risk PCI patients.

In a third-party analysis conducted by the York Health Economics Consortium was evaluated to test the hypothesis that percutaneous coronary intervention (PCI) with Impella® support...